Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion
Q3 2024 Management View CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included ...
BioSpace15h
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
alzheimersnewstoday15h
Leqembi IV monthly maintenance dosing approved by FDA
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
BioArctic stock rises on strong Leqembi sales
Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates. The ...